PARP Inhibition Enhanced Through Combination in Ovarian Cancer
Mansoor Raza Mirza, MD, discusses the initial findings and next steps for the promising niraparib plus bevacizumab combination in ovarian cancer, as well as overall advances with PARP inhibitors in the field.
Source: OncLive